2018 Q2 Form 10-Q Financial Statement
#000156459018021034 Filed on August 09, 2018
Income Statement
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| Revenue | $43.63M | $40.18M |
| YoY Change | 8.58% | 28.12% |
| Cost Of Revenue | $17.73M | $14.70M |
| YoY Change | 20.62% | 43.07% |
| Gross Profit | $25.90M | $25.48M |
| YoY Change | 1.64% | 20.83% |
| Gross Profit Margin | 59.36% | 63.41% |
| Selling, General & Admin | $16.08M | $15.25M |
| YoY Change | 5.4% | 10.92% |
| % of Gross Profit | 62.08% | 59.87% |
| Research & Development | $4.261M | $3.338M |
| YoY Change | 27.65% | 11.83% |
| % of Gross Profit | 16.45% | 13.1% |
| Depreciation & Amortization | $1.878M | $1.471M |
| YoY Change | 27.67% | 5.98% |
| % of Gross Profit | 7.25% | 5.77% |
| Operating Expenses | $20.34M | $18.59M |
| YoY Change | 9.4% | 11.08% |
| Operating Profit | $5.558M | $6.887M |
| YoY Change | -19.3% | 58.36% |
| Interest Expense | $90.00K | |
| YoY Change | ||
| % of Operating Profit | 1.62% | |
| Other Income/Expense, Net | $736.0K | $96.00K |
| YoY Change | 666.67% | -128.24% |
| Pretax Income | $6.294M | $6.983M |
| YoY Change | -9.87% | 74.18% |
| Income Tax | $2.173M | $1.555M |
| % Of Pretax Income | 34.52% | 22.27% |
| Net Earnings | $4.121M | $5.428M |
| YoY Change | -24.08% | 41.5% |
| Net Earnings / Revenue | 9.45% | 13.51% |
| Basic Earnings Per Share | $0.07 | $0.09 |
| Diluted Earnings Per Share | $0.07 | $0.09 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 61.10M | 58.48M |
| Diluted Shares Outstanding | 62.24M | 60.73M |
Balance Sheet
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $145.3M | $160.2M |
| YoY Change | -9.3% | 41.27% |
| Cash & Equivalents | $71.07M | $104.9M |
| Short-Term Investments | $74.30M | $55.40M |
| Other Short-Term Assets | $4.600M | $1.027M |
| YoY Change | 347.91% | -13.99% |
| Inventory | $20.60M | $14.55M |
| Prepaid Expenses | $1.336M | |
| Receivables | $31.60M | $26.73M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $202.2M | $205.7M |
| YoY Change | -1.7% | 40.53% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $23.95M | $20.29M |
| YoY Change | 18.01% | 0.45% |
| Goodwill | $19.48M | |
| YoY Change | -0.3% | |
| Intangibles | $9.343M | |
| YoY Change | -22.27% | |
| Long-Term Investments | $35.80M | |
| YoY Change | ||
| Other Assets | $4.500M | $3.536M |
| YoY Change | 27.26% | 98.21% |
| Total Long-Term Assets | $90.20M | $52.65M |
| YoY Change | 71.31% | -1.67% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $202.2M | $205.7M |
| Total Long-Term Assets | $90.20M | $52.65M |
| Total Assets | $292.4M | $258.4M |
| YoY Change | 13.18% | 29.23% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $9.700M | $9.623M |
| YoY Change | 0.8% | 143.25% |
| Accrued Expenses | $9.800M | $12.09M |
| YoY Change | -18.95% | 45.81% |
| Deferred Revenue | $1.621M | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $21.10M | $23.19M |
| YoY Change | -9.02% | -11.04% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $4.500M | $3.538M |
| YoY Change | 27.19% | 75.32% |
| Total Long-Term Liabilities | $4.500M | $3.538M |
| YoY Change | 27.19% | 75.32% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $21.10M | $23.19M |
| Total Long-Term Liabilities | $4.500M | $3.538M |
| Total Liabilities | $27.20M | $26.73M |
| YoY Change | 1.76% | -4.84% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$132.6M | |
| YoY Change | -19.1% | |
| Common Stock | $374.0M | |
| YoY Change | 8.37% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $265.2M | $229.4M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $292.4M | $258.4M |
| YoY Change | 13.18% | 29.23% |
Cashflow Statement
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $4.121M | $5.428M |
| YoY Change | -24.08% | 41.5% |
| Depreciation, Depletion And Amortization | $1.878M | $1.471M |
| YoY Change | 27.67% | 5.98% |
| Cash From Operating Activities | $6.290M | $9.080M |
| YoY Change | -30.73% | -24.33% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $2.587M | $689.0K |
| YoY Change | 275.47% | -38.54% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $3.880M | -$36.14M |
| YoY Change | -110.74% | |
| Cash From Investing Activities | $1.290M | -$36.83M |
| YoY Change | -103.5% | 3130.7% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 40.00K | 11.24M |
| YoY Change | -99.64% | 12388.89% |
| NET CHANGE | ||
| Cash From Operating Activities | 6.290M | 9.080M |
| Cash From Investing Activities | 1.290M | -36.83M |
| Cash From Financing Activities | 40.00K | 11.24M |
| Net Change In Cash | 7.620M | -16.51M |
| YoY Change | -146.15% | -250.78% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $6.290M | $9.080M |
| Capital Expenditures | $2.587M | $689.0K |
| Free Cash Flow | $3.703M | $8.391M |
| YoY Change | -55.87% | -22.87% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
23946000 | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-55000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-2122000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
2002000 | ||
| CY2017Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
7235000 | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11262000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3746000 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
59755000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-318000 | ||
| CY2018Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
2663000 | |
| CY2017Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-55000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
21372000 | |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
221905000 | |
| us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
255000 | ||
| CY2018Q2 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
1621000 | |
| CY2017Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
1314000 | |
| CY2018Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
43625000 | |
| CY2018Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
17730000 | |
| CY2018Q2 | us-gaap |
Gross Profit
GrossProfit
|
25895000 | |
| CY2018Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4261000 | |
| CY2018Q2 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
7429000 | |
| us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
12500000 | ||
| CY2018Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
736000 | |
| CY2018Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
6294000 | |
| CY2018Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2173000 | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
4121000 | |
| CY2018Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.07 | |
| CY2018Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.07 | |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
26935000 | ||
| CY2017Q2 | us-gaap |
Gross Profit
GrossProfit
|
25477000 | |
| us-gaap |
Gross Profit
GrossProfit
|
50362000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
14842000 | ||
| CY2017Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
14699000 | |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
35250000 | ||
| CY2017Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
40176000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
85612000 | ||
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
72722000 | ||
| CY2017Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3338000 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
23029000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
45302000 | ||
| CY2017Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
96000 | |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
6887000 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
5060000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
22758000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1148000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
563000 | ||
| CY2017Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
6983000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
6208000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
23321000 | ||
| CY2017Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1555000 | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
4206000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
5452000 | ||
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
5428000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
2002000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
17869000 | ||
| CY2017Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.09 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.03 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.31 | ||
| CY2017Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.09 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.03 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.30 | ||
| CY2017Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
58478000 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
60983000 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
57708000 | ||
| CY2017Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
60728000 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
62379000 | ||
| CY2017Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1862000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-3806000 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
2312000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
20126000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
17869000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3631000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2891000 | ||
| us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-178000 | ||
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-322000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2680000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1525000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
4739000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
83000 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
3171000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1970000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-1283000 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
93917000 | ||
| us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
85926000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
4484000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-12475000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1201000 | ||
| CY2018Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
61100000 | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
62244000 | |
| CY2018Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1652000 | |
| CY2018Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
194000 | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-272000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-10166000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
6923000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1429000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-289000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-193000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
253000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-11641000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
13928000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1800000 | ||
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
72869000 | |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
71069000 | |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
11159000 | ||
| us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
665000 | ||
| us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-318000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
21014000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
713000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
21704000 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
62233000 | ||
| us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
18585000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1567000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-45215000 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
1209000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
19805000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
619000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-3087000 | ||
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
109790000 | |
| CY2017Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
106703000 | |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
4325000 | ||
| us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
412000 | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates</font>.<font style="font-style:normal;"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.</font></p></div> | ||
| us-gaap |
Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
|
<div> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:6.25%;text-indent:3.12%;"><font style="text-decoration:underline;">Product sales</font>. <font style="font-style:normal;">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration we are entitled to, net of allowances for any discounts or rebates. </font></p> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:3.12%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net revenues recorded on sales of the OraQuick<sup style="font-size:85%; vertical-align:top">®</sup> In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of operations.</p> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.</p> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-family:Times New Roman;font-size:10pt;"> </p></div> | ||
| us-gaap |
Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
|
<div> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:3.12%;"><font style="text-decoration:underline;">Arrangements with multiple-performance obligations</font><font style="font-style:normal;">. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services. </font></p></div> | ||
| us-gaap |
Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
|
<div> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:3.12%;"><font style="text-decoration:underline;">Deferred Revenue</font><font style="font-style:normal;">. </font><font style="font-style:normal;">We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June 30, 2018 and December 31, 2017 includes customer prepayments of $1,263 and $1,045, respectively. Deferred revenue as of June 30, 2018 and December 31, 2017 also includes $358 and $269, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that rate.</font></p></div> | ||
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
553000 | |
| CY2018Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
11677000 | |
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
2 | ||
| CY2018Q2 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
110968000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
104271000 | |
| CY2018Q2 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | |
| CY2018Q2 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
871000 | |
| CY2018Q2 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
110097000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
103718000 | |
| CY2018Q2 | us-gaap |
Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
|
5010000 | |
| CY2017Q4 | us-gaap |
Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
|
3514000 | |
| CY2017Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
199000 | |
| CY2017Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
10299000 | |
| CY2018Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
284000 | |
| us-gaap |
Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment
ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
|
Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. | ||
| us-gaap |
Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
|
197000 | ||
| CY2015Q2 | osur |
Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
|
1800000 | |
| CY2015Q2 | osur |
Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
|
8600000 | |
| CY2015Q3 | osur |
Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
|
7200000 | |
| CY2018Q2 | osur |
Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
|
962000 | |
| CY2016Q3 | osur |
Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
|
16600000 | |
| CY2016Q3 | osur |
Contract Expiration Period
ContractExpirationPeriod
|
P6Y | |
| CY2016Q3 | osur |
Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
|
7000000 | |
| CY2016Q3 | osur |
Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
|
9600000 | |
| CY2017Q2 | osur |
Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
|
2600000 | |
| CY2018Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
4949000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
9265000 | |
| CY2017Q4 | us-gaap |
Taxes Payable Current And Noncurrent
TaxesPayableCurrentAndNoncurrent
|
6469000 | |
| CY2018Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1211000 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1064000 | |
| CY2018Q2 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
1054000 | |
| CY2017Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
845000 | |
| CY2018Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2623000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3052000 | |
| CY2018Q2 | us-gaap |
Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
|
10000000 | |
| us-gaap |
Line Of Credit Facility Collateral
LineOfCreditFacilityCollateral
|
Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets. | ||
| CY2018Q2 | us-gaap |
Line Of Credit
LineOfCredit
|
0 | |
| CY2017Q4 | us-gaap |
Line Of Credit
LineOfCredit
|
0 | |
| us-gaap |
Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
|
0.00375 | ||
| us-gaap |
Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
|
2019-09-30 | ||
| us-gaap |
Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
|
0 | ||
| us-gaap |
Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
|
0 | ||
| CY2008Q3 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
25000000 | |
| CY2017Q2 | us-gaap |
Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
|
0 | |
| us-gaap |
Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
|
0 | ||
| us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | ||
| CY2018Q2 | osur |
Non Cash Charges Related To Equity Based Compensation Of Retiring Executives And Expenses Associated With Onboarding New Executives
NonCashChargesRelatedToEquityBasedCompensationOfRetiringExecutivesAndExpensesAssociatedWithOnboardingNewExecutives
|
2188000 | |
| osur |
Non Cash Charges Related To Equity Based Compensation Of Retiring Executives And Expenses Associated With Onboarding New Executives
NonCashChargesRelatedToEquityBasedCompensationOfRetiringExecutivesAndExpensesAssociatedWithOnboardingNewExecutives
|
8628000 | ||
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | ||
| CY2018Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1878000 | |
| CY2018Q2 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2587000 |
